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Abstract
Introduction Prophylactic steroid therapy to reduce the
occurrence of postextubation laryngeal edema is controversial.
Only a limited number of prospective trials involve adults in an
intensive care unit. The purpose of this study was to ascertain
whether administration of multiple doses of dexamethasone to
critically ill, intubated patients reduces or prevents the
occurrence of postextubation airway obstruction. Another
specific objective of our study was to investigate whether an
after-effect (that is, a transient lingering benefit) exists 24 hours
after the discontinuation of dexamethasone.
Methods A randomized, placebo-controlled, double-blind trial
was conducted in an adult medical intensive care unit of a
tertiary care hospital. Eighty-six patients who had been intubated
for more than 48 hours with a cuff leak volume (CLV) of less than
110 ml and who met weaning criteria were randomly assigned
to receive either dexamethasone (5 mg; n = 43) or placebo
(normal saline; n = 43) every six hours for a total of four doses
on the day preceding extubation. CLV was measured before the
first injection, one hour after each injection, and 24 hours after
the fourth injection. Extubation was carried out 24 hours after
the last injection. Postextubation obstruction (defined as the
presence of stridor) was recorded within 48 hours of extubation.
Results Administration of dexamethasone during the 24-hour
period preceding extubation resulted in a statistically significant
increase in the CLV (p < 0.05). The significant increase of CLV
and change of CLV relative to baseline tidal volume
(percentage) occurred not only throughout the treatment period,
but also 24 hours after the last dexamethasone injection. The
incidence of postextubation stridor was significantly lower in the
dexamethasone group than in the placebo group (10% [4/40]
versus 27.5% [11/40]; p  = 0.037), whereas there was no
significant difference in reintubation rate between the two
groups (2.5% [1/40] versus 5% [2/40]; p = 0.561).
Conclusion Prophylactic administration of multiple-dose
dexamethasone is effective in reducing the incidence of
postextubation stridor in adult patients at high risk for
postextubation laryngeal edema. The after-effect of
dexamethasone may validate the reduced incidence of
postextubation stridor after multiple doses of dexamethasone.
Trial registration NCT00452062.
Introduction
Laryngotracheal injury related to intubation may cause narrow-
ing of the airway due to edema of the glottis. Laryngeal edema
is more common after endotracheal intubation for more than
3 6  h o u r s  [ 1 ] .  E d e m a  i n  t h i s  r e g i o n  i s  a s s o c i a t e d  w i t h  t h e
increased risks for postextubation stridor, which increase rein-
tubation rate. Reintubation may result in morbidity and mortal-
ity [2-6]. The prevalence of postextubation stridor ranges
between 6% and 37% in intubated patients [7-12]. Because
the presence of an endotracheal tube (ETT) precludes direct
visualization of the upper airway, recognition of the edema due
to laryngotracheal injury is often difficult. However, upper air-
way patency may be assessed indirectly in the intubated
patient by cuff leak test. A reduced cuff leak volume (CLV) can
CI = confidence interval; CLV = cuff leak volume; ETT = endotracheal tube; FiO2 = fraction of inspired oxygen; ICU = intensive care unit; OR = odds 
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predict the occurrence of laryngotracheal edema in high-risk
patients [7-9,13]. Reports indicate that 1% to 17% of inten-
sive care unit (ICU) patients develop postextubation airway
obstruction requiring reintubation [3,4,9,11,14,15]. Mortality
associated with reintubation has been estimated to be as high
as 30% to 40% [4,6]. Factors correlating with the develop-
ment of postextubation stridor include older age, female gen-
der, elevated Acute Physiologic and Chronic Health
Evaluation II score, low Glasgow Coma Scale score, excessive
ETT size, and a prolonged intubation period [10,16-22].
Controversy still exists regarding the effectiveness of prophy-
lactic steroid therapy for patients at risk for postextubation stri-
dor [11,21-25]. Some studies involving postextubation stridor
and analyses of outcomes for those receiving steroids during
intubation have yielded inconclusive or negative results
[11,23]. Only a limited number of randomized trials involving
adults and evaluating the benefits of corticosteroid therapy
prior to extubation have been conducted [21,22]. Moreover,
studies regarding the efficacy of prophylactic corticosteroids
for intubated patients have yielded conflicting results due to
differences in the number of doses, types of corticosteroids,
and timing and methods of administration to adult patients.
In our clinical practice, the extubation was usually performed
one hour after the last injection of multiple prophylactic doses
of dexamethasone in the patients with a CLV of less than 110
ml. Sometimes, due to unpredictable conditions, critically ill
patients need to delay the planned extubation after steroid
treatment. Previous studies reported that most high-risk
patients susceptible to postextubation upper airway edema
who fail extubation require reintubation within 48 to 72 hours
[3,12]. However, little is known about the after-effect of multi-
ple-dose dexamethasone to prevent postextubation stridor.
The present study was conducted to evaluate the effects of
prophylactic multiple-dose dexamethasone for adult ICU
patients who had been intubated for more than 48 hours and
who were undergoing their first elective extubation in an ICU
setting. The specific objectives of our study were to determine
whether multiple doses of dexamethasone are effective to
reduce or prevent postextubation airway obstruction and to
investigate whether an after-effect (that is, a transient lingering




The current study included patients who were admitted to the
adult medical ICU of the Mackay Memorial Medical Center
(Taipei, Taiwan) between 1 October 2004 and 1 March 2006
and who met the inclusion criteria described below. Informed
consent was obtained from the patients or their relatives prior
to entrance in the trial. This study was approved by the Institu-
tional Research Ethics Board.
All patients underwent endotracheal intubation with a high-vol-
ume, low-pressure cuffed tube possessing an internal diame-
ter of 6.5, 7, 7.5, or 8 mm (Hi-Lo EVAC; Mallinckrodt Medical,
Athlone, Ireland). Patients exhibiting excessive movement
were sedated or paralyzed during mechanical ventilation. Rou-
tine nursing care included ETT suctioning every two hours and
as needed to maintain a patent airway.
All patients were older than 18 years of age and met all of the
following weaning criteria: (a) temperature of less than or
equal to 38°C for more than eight hours, (b) discontinuous use
of sedatives, (c) heart rate of more than or equal to 70 beats
per minute and less than or equal to 130 beats per minute, (d)
systolic blood pressure (SBP) of more than or equal to 80 mm
Hg in the absence of vasopressor, (e) fraction of inspired oxy-
gen (FiO2) of less than or equal to 60%, partial pressure of
oxygen (PaO2) of more than or equal to 60 mm Hg, and PaO2/
FiO2 ratio of more than 200, (f) positive end-expiratory pres-
sure (PEEP) of less than or equal to 5 cm H2O, (g) rapid and
shallow ratio of frequency to tidal volume of less than or equal
to 105, (h) minute ventilation of less than or equal to 15 liters
per minute, and (i) pH of more than or equal to 7.3. Supple-
mental oxygen was continued to maintain an oxygen saturation
of more than 95% as measured by a pulse oximeter (Model
513; Novametrix Medical Systems Inc., Wallingford, CT,
USA). The exclusion criterion was either (a) a history of extu-
bation during the same hospitalization or (b) administration of
corticosteroids seven days prior to extubation.
Cuff leak test
The cuff leak test was therefore administered to the patients
who required mechanical ventilation for more than 48 hours
and who fit the above inclusion criteria. Patients were mechan-
ically ventilated in the volume-assisted control mode by a Bird
8400 STi (Bird, a brand of VIASYS Healthcare Inc., Consho-
hocken, PA, USA) with a tidal volume of 10 ml/kg of ideal body
weight, a respiratory rate of 20 breaths per minute, and a zero
PEEP during CLV measurement. The operator-selected inspir-
atory tidal volume of 10 ml/kg of ideal body weight, displayed
as an expiratory tidal volume, was recorded and the balloon
cuff pressure was measured using a control inflator device
(VBM Medizintechnik GmbH, Sulz am Neckar, Germany). The
balloon cuff was deflated, the expiratory tidal volume was
recorded over the six subsequent respiratory cycles, and the
average of the lowest three values was used for subsequent
analyses. The CLV was determined as the difference in the
actual tidal volume before and after cuff deflation [7,10,13,21].
Study protocol
Patients requiring mechanical ventilation for more than 48
hours and exhibiting a CLV of less than 110 ml before planned
extubation were therefore included in the trial. Many investiga-
tors have recommended the use of a pre-extubation cuff leak
test as a screening method for postextubation laryngeal
edema [7,10,13,21], and selected studies have determinedAvailable online http://ccforum.com/content/11/4/R72
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that a CLV of less than 110 ml is an available predictor of pos-
textubation stridor. The cutoff point was based on a previous
report by Miller and Cole [7]. A respiratory therapist, who was
not involved in the patient care, used a table of a computer-
generated randomization list with a block size of 4. This thera-
pist also prepared the study drug and the identical-looking pla-
cebo and entered the data (including the cuff leak
measurements) into a password-protected database.
Patients were randomly assigned to receive intravenous dex-
amethasone (Oradexon, N.V. Organon, Oss, The Netherlands)
5 mg per injection, or normal saline at an equivalent volume
(placebo). The intubation was performed by the attending phy-
sicians and residents in the medical ward, emergency depart-
ment, and medical ICU and prior to admission. Both the
physician and the staff who administered the treatment (that is,
dexamethasone or placebo) were blinded. The ICU physicians
were not apprised of the measurements obtained by the respi-
ratory therapist. On the day preceding extubation, dexametha-
sone or placebo was administered every six hours for a total of
four doses. CLVs were measured before the first injection, one
hour after each injection, and 24 hours after the fourth
injection.
The patients in the non-intervention arm had extubation
promptly after the cuff leak test. Extubation was performed 24
hours after the last injection of dexamethasone or placebo.
Postextubation obstruction (defined as the presence of stridor
heard with the aid of a stethoscope) was recorded within 48
hours of extubation. The presence of an audible, high-pitched
wheeze was an indication for the inhalation of racemic epine-
phrine. The patients with respiratory distress were assigned to
take non-invasive positive-pressure ventilation (bi-level positive
airway pressure, Knightstar-335; Nellcor Puritan Bennett LLC,
Plesanton, CA, USA) by face mask if they failed in response to
two doses of epinephrine inhalation and exhibited at least two
of the following criteria of respiratory distress: (a) respiratory
acidosis (defined as an arterial pH of less than 7.35 with a par-
tial pressure of arterial carbon dioxide of more than 45 mm
Hg), (b) clinical signs suggestive of respiratory-muscle fatigue
or increased respiratory effort (that is, use of accessory mus-
cles, intercostal retraction, or paradoxical motion of the abdo-
men), (c) a respiratory rate of more than 25 breaths per minute
for two consecutive hours, and (d) hypoxemia (defined as an
arterial oxygen saturation of less than 90% or a PaO2 of less
than 80 mm Hg with an FiO2 of more than 50%).
Patients were reintubated with mechanical ventilation support
if they met at least one of the following criteria: (a) a pH of less
than 7.3 with a partial pressure of carbon dioxide increase of
more than 15 mm Hg, (b) a change in mental status rendering
the patient unable to tolerate non-invasive ventilation, (c) a
decrease in the oxygen saturation to less than 85% despite
the use of a high FiO2 (a PaO2 of less than 50 mm Hg with an
FiO2 of more than 70%), (d) lack of improvement in signs of
respiratory-muscle fatigue, (e) hypotension with an SBP of
less than 80 mm Hg for more than 30 minutes despite ade-
quate volume challenge, (f) a diastolic blood pressure drop of
more than 20 mm Hg, or (g) copious secretions that could not
be cleared adequately or that were associated with acidosis,
hypoxemia, or changes in mental status (somnolence, agita-
tion, or diaphoresis).
Statistical analysis
The sample size calculation was based on the preliminary data
obtained in the medical ICU of our hospital. During a six month
period, 45 patients with a CLV of less than 110 ml underwent
planned extubation and 25 of the patients received dexameth-
asone every six hours for a total of four doses in 24 hours, as
decided by the attending physician. Extubation was performed
24 hours after the last dose of dexamethasone. Postextubation
stridor occurred in 1 of the 25 patients given corticosteroids
(4%) and in 7 of 20 patients not given the drug (35%). A sam-
ple size of 60 subjects was therefore calculated for a two-
sided test with a type 1 error of 5% and a power of 90%.
Statistical analyses were conducted using the SPSS software
package (version 13.0; SPSS Inc., Chicago, IL, USA). Univar-
iate analyses between the dexamethasone and placebo
groups were conducted using Student t tests for continuous
variables and a Pearson chi-square test for categorical varia-
bles, or the Fisher exact test, as indicated. For all tests, a p
value of less than 0.05 was considered statistically significant.
Results
Of all the 386 patients going through the CLV test, 300 had a
CLV of more than or equal to 110 ml and comprised the non-
intervention arm. Fifteen patients were excluded because of
self-extubation (n = 6) or a deterioration in clinical status (n =
9). The patients in the non-intervention group were extubated
at once after the cuff leak test.
Eighty-six patients with a CLV of less than 110 ml met the
inclusion criteria. These patients comprised the intervention
arm and were randomly assigned into the dexamethasone
group (n = 43) and the placebo group (n = 43). In the dexam-
ethasone group, 3 patients withdrew due to respiratory failure
(n = 1), self-extubation (n = 1), and atrial fibrillation with tach-
ycardia (n = 1). In the placebo group, 3 patients withdrew due
to respiratory failure (n = 1), pulmonary edema (n = 1), and a
short run of ventricular tachycardia (n  = 1). A total of 80
patients were therefore analyzed. The randomized disposition
of the patients is shown in Figure 1. The dexamethasone and
placebo groups did not significantly differ in the demographic
characteristics, including age, gender, weight, height, duration
of intubation, diameter of ETT, Glasgow Coma Scale score,
underlying disease, and severity of illness (Table 1).
The measurements of CLV after each injection of dexametha-
sone or placebo, given at the interval of six hours, are shownCritical Care    Vol 11 No 4    Lee et al.
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in Figure 2, and change of CLV relative to baseline tidal volume
(percentage) is shown in Figure 3. Compared to the placebo
group, a significant increase of CLV was noted in the dexam-
ethasone group. The significant difference initially manifested
at the first dexamethasone injection and was consistently
noted after each dexamethasone injection. At the end of our
observation period (that is, 24 hours after the last injection),
the CLV in the dexamethasone group was still significantly
higher than in the placebo group. Thus, the effect of multiple-
dose dexamethasone in increasing CLV occurred not only
throughout the treatment period, but also in the observation
period of 24 hours after the last dexamethasone injection.
The incidence of postextubation stridor was 4.9% (14/285) in
the non-intervention arm, 10% (4/40) in the dexamethasone
group, and 27.5% (11/40) in the placebo group. The absolute
risk reduction and number needed to treat for postextubation
stridor were 18% and 5.7, respectively. Postextubation stridor
was significantly different between the dexamethasone and
the placebo groups (p = 0.037; odds ratio [OR] for stridor:
0.214; 95% confidence interval [CI]: 0.055 to 0.838). Each of
the 29 patients with stridor received epinephrine by inhalation,
and 24 of these patients underwent non-invasive positive-
pressure ventilation: 3 in the dexamethasone group (7.5%), 9
in the placebo group (22.5%), and 12 in the non-intervention
arm (4.2%).
Reintubation with mechanical support was necessary in 2.5%
(1/40) of patients in the dexamethasone group, 5% (2/40) in
the placebo group, and 1.4% (4/285) in the non-intervention
arm. However, the difference in the reintubation rate was not
statistically significant between the dexamethasone and the
placebo groups (p = 0.56; OR for reintubation: 0.49; 95% CI:
0.04 to 5.60). During the period of our study, no patients
exhibited gastrointestinal bleeding, gastric pain or irritation,
acne, psychiatric disturbances (including personality changes,
irritability, euphoria, and mania), or cushingoid features.
Discussion
The potential benefit of steroids to laryngeal edema is presum-
ably based on its anti-inflammatory actions, which inhibit the
release of inflammatory mediators and decrease capillary per-
meability. The risk of harm from steroid therapy for 24 hours or
less to prevent postextubation laryngeal edema is negligible
[22,25,26]. The extent of the effect of prophylactic steroids on
airway obstruction is still a matter of some controversy. A sin-
gle injection of dexamethasone (1 mg/kg) one hour before
extubation had no effect on subglottic injury in a rabbit model
[27]. In a study on unselected adult patients, an 8-mg injection
of dexamethasone given one hour before extubation did not
reduce the number of patients requiring reintubation [1].
Another study on children reported that six doses of dexame-
thasone (0.5 mg/kg) given every six hours starting 6 to 12
hours before extubation had no effect on the incidence of pos-
textubation stridor [23]. Contrary to the previous studies, the
positive results were reported by other studies, most of which
were conducted on pediatric patient populations. Four doses
of dexamethasone (0.25 mg/kg) given at eight hour intervals
could prevent stridor in preterm infants [28]. Six doses of dex-
amethasone (0.5 mg/kg) given every six hours were also effec-
tive in preventing postextubation stridor for intubated children
in the ICU [24]. A meta-analysis concluded that prophylactic
Figure 1
Study flowchart Study flowchart. CLV, cuff leak volume.Available online http://ccforum.com/content/11/4/R72
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dexamethasone reduces postextubation stridor in infants and
children [25]. In a comparison study, one 2-mg dose of neb-
ulized budesonide was as effective as a single intravenous
dose of dexamethasone (0.6 mg/kg) in treating symptoms in
children with croup [29].
We conducted this randomized clinical trial to evaluate the
effects of prophylactic dexamethasone therapy in preventing
laryngeal edema for adult patients with a CLV of less than 110
ml in an adult medical ICU setting. The choice of dexametha-
sone was based on its high anti-inflammatory potency, negligi-
ble mineralocorticoid effects at therapeutic doses, and long
duration of action [30]. To our knowledge, this was the first
study to periodically monitor the CLV after each dexametha-
sone administration and to investigate the after-effect until 24
hours after the last dose of dexamethasone. Our results
revealed the significant reduction of postextubation stridor
(10% in the dexamethasone group and 27.5% in the placebo
group) and reintubation rate (2.5% in the dexamethasone
group and 5% in the placebo group). Moreover, CLV and the
ratio of CLV to tidal volume significantly increased, and this
effect occurred not only throughout the treatment period, but
also 24 hours after the last dexamethasone injection.
Our findings of steroid effect in reducing postextubation stri-
dor were consistent with the results of the two recent studies
in adult medical and surgical ICU settings [21,22]. Cheng and
colleagues [21] reported that low CLV with less than 24% of
Table 1
Demographic data of patients.
Dexamethasone group (n = 40) Placebo group (n = 40) P value
Age (years)a 72.4 ± 14.7 72.7 ± 13.8 0.55
Genderb 0.66
Female 34 (85) 32 (88)
Male 6 (15) 8 (12)
Body weight (kg)a 58.6 ± 9.6 57.5 ± 10.6 0.68
Height (cm)a 155.8 ± 6.9 152.9 ± 7.3 0.10
APACHE II scorea 19.5 ± 2.9 21.5 ± 3.7 0.08
Albumin (g/dl)a 2.6 ± 0.6 2.5 ± 0.6 0.98
Hemoglobin (g/dl)a 9.7 ± 1.7 9.4 ± 1.3 0.30
Internal diameter of endotracheal tubeb 0.14
6.5 or 7 mm 5 (12) 4 (10)
7.5 or 8.0 mm 35 (88) 36 (90)
Intubation time (hours)a 167.3 ± 48.1 158.5 ± 49.0 0.95
Reason for intubationb 0.94
Pneumonia 11 (28) 9 (23)
Sepsis 4 (10) 5 (13)
Heart failure 4 (10) 5 (13)
Acute respiratory distress syndrome 2 (5) 3 (8)
Chronic obstructive pulmonary disease 5 (13) 4 (10)
Asthma 0 1 (3)
Other 14 (35) 13 (33)




aData are presented as mean ± standard deviation; bdata are presented as number of patients (percentage of patients). APACHE II, Acute 
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tidal volume could be a useful predictor of postextubation stri-
dor. Four prophylactic infusions of 40 mg of methylpred-
nisolone, given at six hour intervals to high-risk adult patients
with low CLV, significantly decreased the incidence of postex-
tubation stridor from 30.2% to 7.1% and the reintubation rate
from 18.6% to 7.1% [21]. In a recent study with a large
number of subjects, Francois and colleagues [22] reported
that four doses of 20 mg of methylprednisolone, given at four
hour intervals, significantly reduced the incidence of postextu-
bation stridor from 22% to 3% and reduced the incidence of
reintubation from 8% to 4%. However, the subjects in this
study were not restricted to the high-risk patients for postextu-
bation laryngeal edema (unlike the subjects in our study).
The effects in the reduction of postextubation stridor may be
influenced by varied cutoff points based on CLV. Cheng and
colleagues [21] used low CLV with less than 24% of tidal vol-
ume and set the tidal volume at 8 mg/kg of ideal body weight.
However, we adopted the criterion of CLV of less than 110 ml
and the tidal volume was set at 10 ml/kg of ideal body weight
[7,10,13]. The reduction of postextubation stridor in our study
was statistically significant, but not as dramatic as that of the
study of Cheng and colleagues. Another reason for this
discrepancy may be the difference in the timing of extubation.
Cheng and colleagues executed the extubation one hour after
methylprednisolone administration over the span of 24 hours.
To monitor the CLV level and check the after-effect of dexam-
ethasone administration for 24 hours, we delayed the extuba-
tion until 24 hours after the last dexamethasone injection. The
after-effect of dexamethasone validates the reduced incidence
of postextubation stridor after multiple doses of
dexamethasone.
In regard to the reintubation rate, there was no significant dif-
ference between the dexamethasone-treated and the placebo
groups in our study, whereas the reintubation rates of our sub-
jects (2.5% in the dexamethasone group and 5% in the pla-
cebo group) were lower than those of Cheng and colleagues
[21] (7.1% in the methylprednisolone group and 18.6% in the
placebo group) and Francois and colleagues [22] (4% in the
methylprednisolone group and 8% in the placebo group). The
different results among these studies may be explained by the
difference in the types of corticosteroids, risk factors predis-
posing to laryngeal edema, monitoring duration after extuba-
tion, and treatments for postextubation stridor.
Our study and the other two studies mentioned here substan-
tiated that corticosteroids confer the benefits on adult patients
at high risk for postextubation laryngeal edema, whereas a rou-
tine prophylactic use of corticosteroids to prevent postextuba-
tion stridor in every intubated patient is unwarranted.
Dexamethasone and other steroids, in appropriate doses, can
be helpful in alleviating laryngeal edema in intubated high-risk
patients susceptible to airway obstruction, such as those
requiring repeated or prolonged intubations.
Figure 2
Cuff leak volumes for critically ill patients receiving injections of dexam- ethasone or placebo (normal saline) before extubation Cuff leak volumes for critically ill patients receiving injections of dexam-
ethasone or placebo (normal saline) before extubation. Patients who 
had been intubated for more than two days and who exhibited cuff leak 
volumes of less than 110 ml at T = 0 received injections at 6, 12, 18, 
and 24 hours, followed by extubation. Cuff leak tests were measured at 
T = 0, 1 hour after each injection, and 24 hours after the fourth injec-
tion. Differences in cuff leak volumes between the two groups were sig-
nificant (*P < 0.05).
Figure 3
Cuff leak volumes for critically ill patients receiving injections of dexam- ethasone or placebo (normal saline) before extubation Cuff leak volumes for critically ill patients receiving injections of dexam-
ethasone or placebo (normal saline) before extubation. Patients who 
had been intubated for more than two days and who exhibited cuff leak 
volumes of less than 110 ml at T = 0 received injections at 6, 12, 18, 
and 24 hours, followed by extubation. Differences in change of cuff leak 
volume relative to baseline tidal volume (percentage) between the two 
groups were significant (*P < 0.05).Available online http://ccforum.com/content/11/4/R72
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Conclusion
Dexamethasone, a long-acting and potent corticosteroid, is
suitable for preventing postextubation airway edema. Adminis-
tration of multiple prophylactic doses of dexamethasone signif-
icantly decreases the incidence of postextubation stridor in
adult patients at high risk to develop airway obstruction. The
after-effect of dexamethasone may validate the reduced inci-
dence of postextubation stridor after multiple-dose
dexamethasone.
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